These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38960588)

  • 1. Treatment drop-in in a contemporary cohort used to derive cardiovascular risk prediction equations.
    Liang J; Jackson RT; Pylypchuk R; Choi Y; Chung C; Crengle S; Gao P; Grey C; Harwood M; Holt A; Kerr A; Mehta S; Wells S; Poppe K
    Heart; 2024 Aug; 110(17):1083-1089. PubMed ID: 38960588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
    Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
    Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of alternative cardiovascular risk prediction equations for population health planning: a routine health data linkage study of 1.7 million New Zealanders.
    Mehta S; Jackson R; Pylypchuk R; Poppe K; Wells S; Kerr AJ
    Int J Epidemiol; 2018 Oct; 47(5):1571-1584. PubMed ID: 30010781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do cardiovascular risk prediction equations developed among 30-74 year olds perform in older age groups? A validation study in 125 000 people aged 75-89 years.
    Mehta S; Jackson R; Poppe K; Kerr AJ; Pylypchuk R; Wells S
    J Epidemiol Community Health; 2020 Jun; 74(6):527-533. PubMed ID: 32144211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular preventive pharmacotherapy stratified by predicted cardiovascular risk: a national data linkage study.
    Mehta S; Zhao J; Poppe K; Kerr AJ; Wells S; Exeter DJ; Selak V; Grey C; Jackson R
    Eur J Prev Cardiol; 2022 Feb; 28(17):1905-1913. PubMed ID: 33580793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15).
    Mehta S; Wells S; Riddell T; Kerr A; Pylypchuk R; Marshall R; Ameratunga S; Chan WC; Thornley S; Crengle S; Harrison J; Drury P; Elley CR; Bell F; Jackson R
    J Prim Health Care; 2011 Jun; 3(2):93-101. PubMed ID: 21625656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular medication changes over 5 years in a national data linkage study: implications for risk prediction models.
    Mehta S; Jackson R; Wells S; Harrison J; Exeter DJ; Kerr AJ
    Clin Epidemiol; 2018; 10():133-141. PubMed ID: 29391835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study.
    Pylypchuk R; Wells S; Kerr A; Poppe K; Harwood M; Mehta S; Grey C; Wu BP; Selak V; Drury PL; Chan WC; Orr-Walker B; Murphy R; Mann J; Krebs JD; Zhao J; Jackson R
    Lancet; 2021 Jun; 397(10291):2264-2274. PubMed ID: 34089656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study.
    Pylypchuk R; Wells S; Kerr A; Poppe K; Riddell T; Harwood M; Exeter D; Mehta S; Grey C; Wu BP; Metcalf P; Warren J; Harrison J; Marshall R; Jackson R
    Lancet; 2018 May; 391(10133):1897-1907. PubMed ID: 29735391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease?
    Selak V; Jackson R; Poppe K; Kerr A; Wells S
    N Z Med J; 2018 Oct; 131(1484):19-25. PubMed ID: 30359352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia.
    Banks E; Crouch SR; Korda RJ; Stavreski B; Page K; Thurber KA; Grenfell R
    Med J Aust; 2016 May; 204(8):320. PubMed ID: 27125809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of cardiovascular risk prediction equations in 76 000 people with known cardiovascular disease.
    Holt A; Batinica B; Liang J; Kerr A; Crengle S; Hudson B; Wells S; Harwood M; Selak V; Mehta S; Grey C; Lamberts M; Jackson R; Poppe KK
    Eur J Prev Cardiol; 2024 Jan; 31(2):218-227. PubMed ID: 37767960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions.
    Hageman SHJ; Kaptoge S; de Vries TI; Lu W; Kist JM; van Os HJA; Numans ME; Läll K; Bobak M; Pikhart H; Kubinova R; Malyutina S; Pająk A; Tamosiunas A; Erbel R; Stang A; Schmidt B; Schramm S; Bolton TR; Spackman S; Bakker SJL; Blaha M; Boer JMA; Bonnefond A; Brenner H; Brunner EJ; Cook NR; Davidson K; Dennison E; Donfrancesco C; Dörr M; Floyd JS; Ford I; Fu M; Gansevoort RT; Giampaoli S; Gillum RF; Gómez-de-la-Cámara A; Håheim LL; Hansson PO; Harms P; Humphries SE; Ikram MK; Jukema JW; Kavousi M; Kiechl S; Kucharska-Newton A; Pablos DL; Matsushita K; Meyer HE; Moons KGM; Mortensen MB; Muilwijk M; Nordestgaard BG; Packard C; Pamieri L; Panagiotakos D; Peters A; Potier L; Providencia R; Psaty BM; Ridker PM; Rodriguez B; Rosengren A; Sattar N; Schöttker B; Schwartz JE; Shea S; Shipley MJ; Sofat R; Thorand B; Verschuren WMM; Völzke H; Wareham NJ; Westbury L; Willeit P; Zhou B; Danesh J; Visseren FLJ; Di Angelantonio E; Pennells L; Dorresteijn JAN
    Eur J Prev Cardiol; 2024 Oct; 31(14):1690-1699. PubMed ID: 38752762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and population description of the CREDENCE study: cardiovascular risk equations for diabetes patients from New Zealand and Chinese electronic health records.
    Liang J; Pylypchuk R; Tang X; Shen P; Liu X; Chen Y; Tan J; Wu J; Zhang J; Lu P; Lin H; Gao P; Jackson R
    Eur J Epidemiol; 2021 Oct; 36(10):1085-1095. PubMed ID: 34420154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1).
    Kerr A; Exeter D; Hanham G; Grey C; Zhao J; Riddell T; Lee M; Jackson R; Wells S
    N Z Med J; 2014 Aug; 127(1400):39-69. PubMed ID: 25145366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular disease preventive medication dispensing for almost every New Zealander 65 years and over: a preventive treatment paradox?
    Wells S; Choi Y; Jackson R; Parwaiz M; Mehta S; Selak V; Harwood M; Grey C; Kerse N; Poppe K
    Age Ageing; 2022 Jan; 51(1):. PubMed ID: 35077560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of CVD risk equations for older patients assessed in general practice: a cohort study.
    Wells S; Pylypchuk R; Mehta S; Kerr A; Selak V; Poppe K; Grey C; Jackson R
    N Z Med J; 2020 Jun; 133(1517):32-55. PubMed ID: 32595220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are competing-risk models superior to standard Cox models for predicting cardiovascular risk in older adults? Analysis of a whole-of-country primary prevention cohort aged ≥65 years.
    Cooper H; Wells S; Mehta S
    Int J Epidemiol; 2022 May; 51(2):604-614. PubMed ID: 34109395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observational study of how clinicians use cardiovascular risk assessment to inform statin prescribing decisions.
    Robinson T; Jackson R; Wells S; Kerr A; Marshall R
    N Z Med J; 2017 Oct; 130(1463):28-38. PubMed ID: 28981492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.